108 related articles for article (PubMed ID: 5670722)
1. Influence of route of administration on antileukemic activity of cytosine arabinoside (NSC-63878) in advanced leukemia L1210 in mice.
Kline I; Tyrer DD; Gang M; Venditti JM; Goldin A
Cancer Chemother Rep; 1968 Apr; 52(3):399-404. PubMed ID: 5670722
[No Abstract] [Full Text] [Related]
2. Studies of the L1210 antileukemic activity of O-2,2'-cyclocytidine, monoacetate (anhydro-ara-C; NSC-129220)--comparison with cytosine arabinoside (NSC-63878) with respect to treatment schedule dependency.
Venditti JM; Baratta MC; Greenberg NH; Abbott BJ; Kline I
Cancer Chemother Rep; 1972 Aug; 56(4):483-92. PubMed ID: 5081591
[No Abstract] [Full Text] [Related]
3. Influence of mitotic cycle inhibitors on the antileukemic activity of cytosine arabinoside (NSC-63878) in mice bearing leukemia L1210.
Vadlamudi S; Goldin A
Cancer Chemother Rep; 1971 Dec; 55(5):547-55. PubMed ID: 5159846
[No Abstract] [Full Text] [Related]
4. Sequential chemotherapy with cyclophosphamide (NSC-26271) and cytosine arabinoside (NSC-63878) in mice with advanced leukemia L1210.
Hoffman GS; Kline I; Gang M; Tyrer DD; Goldin A; Mantel N; Venditti JM
Cancer Chemother Rep; 1969 Oct; 53(5):265-71. PubMed ID: 5377613
[No Abstract] [Full Text] [Related]
5. [Selective treatment of leukemia L1210 with combination of deoxycytidine and lethal doses of cytosine arabinoside].
Bukhman VM; Lichinitser MR; Svet-Moldavskiĭ GIa; Mkheidze DM
Biull Eksp Biol Med; 1978 Mar; 85(3):340-3. PubMed ID: 276385
[TBL] [Abstract][Full Text] [Related]
6. Effect of different doses of methotrexate (NSC-740), cytosine arabinoside (NSC-63878), and cyclophosphamide (NSC-26271) on drug resistance in mice with L1210 leukemia.
Schmid FA; Hutchison DJ
Cancer Chemother Rep; 1972 Aug; 56(4):473-81. PubMed ID: 5081590
[No Abstract] [Full Text] [Related]
7. Influence of the stage of advancement of leukemia L1210 in mice on the optimal schedule of treatment of cytosine arabinoside (NSC-63878).
Kline I; Woodman RJ; Gang M; Sirica A; Venditti JM; Goldin A
Cancer Chemother Rep; 1972 Jun; 56(3):327-34. PubMed ID: 19051491
[TBL] [Abstract][Full Text] [Related]
8. A computer model for tumor growth and chemotherapy, and its application to L1210 leukemia treated with cytosine arabinoside (NSC-63878).
Shackney SE
Cancer Chemother Rep; 1970 Dec; 54(6):399-429. PubMed ID: 5527022
[No Abstract] [Full Text] [Related]
9. Selective chemotherapy for advanced murine L 1210 leukemia by combination of 2' deoxycytidine and lethal doses of cytosine-arabinoside.
Buchman VM; Svet-Maoldavsky GJ; Lichinitser MR; Mkheidze DM
Biomedicine; 1977 Jul; 27(5):179-80. PubMed ID: 922116
[TBL] [Abstract][Full Text] [Related]
10. Value of cytosine arabinoside (NSC-63878) plus 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) therapy in advanced murine L1210 leukemia and enhancement of the combination with sequential doses of methotrexate (NSC-740) or 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962).
Kline I; Woodman RJ; Gang M; Cysyk RL; Venditti JM
Cancer Chemother Rep; 1973; 57(3):291-8. PubMed ID: 4751255
[No Abstract] [Full Text] [Related]
11. Chronochemotherapy of L1210 leukemic mice with cytosine arabinoside or cyclophosphamide.
Rose WC; Trader MW; Laster WR; Schabel FM
Cancer Treat Rep; 1978 Sep; 62(9):1337-49. PubMed ID: 688277
[No Abstract] [Full Text] [Related]
12. Antitumor activity of prolonged-release derivative of cytosine arabinoside, cytosine arabinoside-agarose conjugate.
Hashida M; Kojima T; Muranishi S; Sezaki H
Gan; 1978 Dec; 69(6):839-43. PubMed ID: 750275
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of the cancer chemotherapeutic effect of cytosine arabinoside entrapped in liposomes on mouse leukemia L-1210.
Kobayashi T; Tsukagoshi S; Sakurai Y
Gan; 1975 Dec; 66(6):719-20. PubMed ID: 1225724
[No Abstract] [Full Text] [Related]
14. Role of liposome type and route of administration in the antitumor activity of liposome-entrapped 1-beta-D-arabinofuranosylcytosine against mouse L1210 leukemia.
Rustum YM; Dave C; Mayhew E; Papahadjopoulos D
Cancer Res; 1979 Apr; 39(4):1390-5. PubMed ID: 421223
[No Abstract] [Full Text] [Related]
15. Antitumor effect of 1-beta-D-arabinofuranosylcytosine 5'-adamantoate (NSC 117614) in L1210 leukemic mice.
Neil GL; Wiley PF; Manak RC; Moxley TE
Cancer Res; 1970 Apr; 30(4):1047-54. PubMed ID: 5504347
[No Abstract] [Full Text] [Related]
16. Role of cholesterol in enhancing the antitumor activity of cytosine arabinoside entrapped in liposomes.
Mayhew E; Rustum YM; Szoka F; Papahadjopoulos D
Cancer Treat Rep; 1979; 63(11-12):1923-8. PubMed ID: 526925
[No Abstract] [Full Text] [Related]
17. Cytosine arabinoside (NSC-63878)--clinical brochure.
Livingston RB; Carter SK
Cancer Chemother Rep 3; 1968 Dec; 1(1):179-205. PubMed ID: 4989814
[No Abstract] [Full Text] [Related]
18. Effect of combined therapy with cytosine arabinoside (NSC-63878) and l,3-bis-(2-chloroethyl)-1-nitrosourea (NSC-409962) on sarcoma 180 and L1210 in vivo.
Mizuno NS; Humphrey EW
Cancer Chemother Rep; 1969 Sep; 53(4):215-21. PubMed ID: 5384462
[No Abstract] [Full Text] [Related]
19. Dose-related synergism of cytosine arabinoside and methotrexate against murine leukemia L1210.
Avery TL; Roberts D
Eur J Cancer (1965); 1974 Jul; 10(7):425-9. PubMed ID: 4457345
[No Abstract] [Full Text] [Related]
20. [Antileukemic activity of liposome forms of cytosine arabinoside and cyclocytidine].
Reshchikov VP; Afonin NI; Ermakov LN; Fertukova NM; Oksinoĭd OE
Gematol Transfuziol; 1984; 29(5):49-51. PubMed ID: 6203808
[No Abstract] [Full Text] [Related]
[Next] [New Search]
